Bayer, Dewpoint take aim at heart disease, women's health in deal worth up to $100M

Amir Nashat headshot
The deal could be worth up to $100 million, but Dewpoint and Bayer didn't break down that figure further. (Polaris Partners)

Dewpoint Therapeutics, the biotech working to drug biomolecular condensates, has struck its first big deal. It’s teaming up with Bayer on new treatments for a pair of neglected fields: heart disease and women’s health. 

The multiyear deal could be worth up to $100 million, but the duo did not break that figure down further. They will put Dewpoint’s condensates technology and Bayer’s small molecule library and R&D expertise to work, with the German pharma picking up the option to license a “specified number” of programs from the deal. 

Dewpoint isn’t disclosing which specific diseases the partners are interested in, but CEO Amir Nashat pointed to pathways in both areas that are well known but have been difficult to drug safely. Using condensates will open up new targets, new epitopes and new binding sites for drug discovery and development, he said. 

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

RELATED: FierceBiotech’s 2019 Fierce 15 | Dewpoint Therapeutics 

Biomolecular condensates are membraneless organelles whose main job is to surround and contain reactants—such as proteins and nucleic acids—for chemical reactions within cells. Although researchers and drug developers have long known about condensates, they have been “understudied” because they are difficult to analyze with conventional drug discovery methods. 

“Condensates are everywhere—they’re found in all cell types and they’re relevant to all diseases,” Mark Murcko, Dewpoint’s chief scientific officer, told FierceBiotech. “Our mission is to figure out how we can take that knowledge and transform that into great new drugs to treat patients who would otherwise have no options.” 

Given the vast applicability of the approach, why did Dewpoint zero in on cardiovascular and gynecological diseases? 

“Condensates are a new angle for new targets—a new approach in two spaces that have been pretty neglected for different reasons,” Nashat said. “Women’s health has always been neglected and cardiovascular disease has become neglected … It’s kind of cool to breathe new life into those areas using a new approach.”

RELATED: Polaris launches Dewpoint Therapeutics with $60M to drug biomolecular condensates

But heart disease and women’s health aren’t areas that Dewpoint could have attacked on its own: “We don’t have anywhere near the expertise and infrastructure those guys [at Bayer] do,” Nashat said. 

It’s part of the reason the biotech—which is based in Cambridge, Massachusetts, and Dresden, Germany—went with Bayer. It’s one of the companies that is a leader in, and continues to invest in, both spaces. 

As for its internal pipeline? Dewpoint isn’t ready to unveil that yet. But given the “natural history” of the company’s founding and the specialties of its founders, its initial focus is likely to be cancer and neurodegenerative diseases.

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.